David Gruben

8.0k total citations · 6 hit papers
101 papers, 6.3k citations indexed

About

David Gruben is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, David Gruben has authored 101 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Rheumatology, 45 papers in Hematology and 21 papers in Immunology. Recurrent topics in David Gruben's work include Rheumatoid Arthritis Research and Therapies (68 papers), Autoimmune and Inflammatory Disorders Research (45 papers) and Chronic Lymphocytic Leukemia Research (19 papers). David Gruben is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (68 papers), Autoimmune and Inflammatory Disorders Research (45 papers) and Chronic Lymphocytic Leukemia Research (19 papers). David Gruben collaborates with scholars based in United States, Canada and United Kingdom. David Gruben's co-authors include Samuel H. Zwillich, Gene V. Wallenstein, Sriram Krishnaswami, Roy Fleischmann, John Bradley, Joel M. Kremer, Bethanie Wilkinson, Tamás Koncz, Carol A. Connell and Eun Bong Lee and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

David Gruben

97 papers receiving 6.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

2012 790 citations Roy Fleischmann, Joel M. Kremer et al. New England Journal of Medicine profile →
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

2012 739 citations Ronald van Vollenhoven, Roy Fleischmann et al. New England Journal of Medicine profile →
Tofacitinib versus Methotrexate in Rheumatoid Arthritis

2014 598 citations Eun Bong Lee, Roy Fleischmann et al. New England Journal of Medicine profile →
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

2013 548 citations Cristiano A. F. Zerbini, Birgitta Benda et al. profile →
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

2013 456 citations Désirée van der Heijde, Yoshiya Tanaka et al. Arthritis & Rheumatism profile →
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

2013 366 citations Joel M. Kremer, Zhanguo Li et al. Annals of Internal Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Gruben United States	29	4.4k	2.5k	1.5k	1.4k	1.4k	101	6.3k
Sriram Krishnaswami United States	32	3.9k 0.9×	2.2k 0.9×	1.4k 1.0×	1.3k 0.9×	1.4k 1.0×	59	6.1k
Samuel H. Zwillich United States	34	5.3k 1.2×	2.8k 1.1×	1.8k 1.2×	1.7k 1.2×	1.8k 1.3×	89	7.7k
Patrick Durez Belgium	38	5.1k 1.2×	2.4k 1.0×	2.2k 1.5×	1.3k 0.9×	690 0.5×	205	7.2k
Maya H Buch United Kingdom	42	3.9k 0.9×	1.4k 0.5×	1.7k 1.2×	996 0.7×	575 0.4×	211	6.4k
Maria Greenwald United States	30	2.7k 0.6×	1.2k 0.5×	1.5k 1.0×	868 0.6×	1.2k 0.9×	76	5.1k
Andrea Rubbert‐Roth Germany	33	3.3k 0.7×	1.5k 0.6×	1.7k 1.1×	885 0.6×	647 0.5×	123	5.1k
Terence Rooney United States	28	2.9k 0.6×	1.4k 0.6×	806 0.5×	857 0.6×	932 0.7×	53	3.9k
Hideto Kameda Japan	38	2.6k 0.6×	1.2k 0.5×	1.2k 0.8×	631 0.5×	398 0.3×	196	4.3k
Xavier Le Loët France	42	3.3k 0.8×	1.3k 0.5×	1.4k 0.9×	644 0.5×	328 0.2×	198	5.4k
Sujatha Menon United States	22	2.3k 0.5×	1.1k 0.4×	1.3k 0.9×	327 0.2×	702 0.5×	55	3.6k

Countries citing papers authored by David Gruben

Since Specialization

Citations

This map shows the geographic impact of David Gruben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gruben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gruben more than expected).

Fields of papers citing papers by David Gruben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gruben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gruben. The network helps show where David Gruben may publish in the future.

Co-authorship network of co-authors of David Gruben

This figure shows the co-authorship network connecting the top 25 collaborators of David Gruben. A scholar is included among the top collaborators of David Gruben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gruben. David Gruben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jairath, Vipul, Tim Raine, Thomas P. Leahy, et al.. (2025). Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis. Journal of Comparative Effectiveness Research. 14(4). e240193–e240193.

Al‐Emadi, Samar, et al.. (2025). Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials. BMJ Open. 15(12). e082366–e082366. 1 indexed citations

Armuzzi, Alessandro, David T. Rubin, S Schreiber, et al.. (2024). Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflammatory Bowel Diseases. 31(6). 1583–1594. 1 indexed citations

Jairath, Vipul, et al.. (2024). P849 Bayesian network meta-analysis of the efficacy of advanced therapies for patients with moderately to severely active ulcerative colitis naïve to advanced therapy. Journal of Crohn s and Colitis. 18(Supplement_1). i1566–i1567. 2 indexed citations

Alten, Rieke, et al.. (2023). High Usability and Applicability Ratings for the New SmartClic®/ClicWise® Injection Device: Evidence from a Health Care Professional Opinion Study. Rheumatology and Therapy. 10(2). 477–487. 1 indexed citations

Eder, Lihi, Dafna D. Gladman, Philip J. Mease, et al.. (2023). Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 9(1). e002718–e002718. 14 indexed citations

Citera, Gustavo, Rakesh K. Jain, Fedra Irazoque-Palazuelos, et al.. (2020). THU0196 TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INDICATIVE OF DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 CLINICAL TRIALS. Annals of the Rheumatic Diseases. 79. 318–319. 3 indexed citations

Claxton, Lindsay, Matthew Taylor, Robert A. Gerber, et al.. (2018). Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Current Medical Research and Opinion. 34(11). 1991–2000. 16 indexed citations

Gerber, Robert A., et al.. (2017). Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. International Journal of Rheumatology. 2017. 1–15. 26 indexed citations

10.

Landewé, Robert, Carol A. Connell, John Bradley, et al.. (2016). Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. Arthritis Research & Therapy. 18(1). 212–212. 24 indexed citations

11.

Genovese, Mark C., Ronald van Vollenhoven, Bethanie Wilkinson, et al.. (2016). Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Research & Therapy. 18(1). 145–145. 15 indexed citations

12.

Harnett, James, Jeffrey R. Curtis, R. Gerber, David Gruben, & Andrew Koenig. (2015). SAT0226 Early Experience with Tofacitinib: Treatment Patterns in Two us Healthcare Claims Databases. Annals of the Rheumatic Diseases. 74. 740–740. 2 indexed citations

13.

Lee, Eun Bong, Roy Fleischmann, Stephen Hall, et al.. (2014). Tofacitinib versus Methotrexate in Rheumatoid Arthritis. New England Journal of Medicine. 370(25). 2377–2386. 598 indexed citations breakdown →

14.

Strand, Vibeke, et al.. (2013). ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis. Data Archiving and Networked Services (DANS). 3 indexed citations

15.

Kremer, Joel, Zhanguo Li, Stephen Hall, et al.. (2013). Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. Annals of Internal Medicine. 5 indexed citations

16.

Heijde, D. van der, Yoshiya Tanaka, R Fleischmann, et al.. (2012). Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study. Arthritis & Rheumatism. 64(10). 4 indexed citations

17.

Fleischmann, Roy, et al.. (2012). THU0153 Improvements in disease activity score by baseline status: Pooled analysis of five phase 3 studies with tofacitinib (CP-690,550) in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 71. 207–207.

18.

Fleischmann, Roy, Maurizio Cutolo, Mark C. Genovese, et al.. (2011). Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs. Arthritis & Rheumatism. 64(3). 617–629. 315 indexed citations

19.

Coombs, John, Bradley J. Bloom, F. C. Breedveld, et al.. (2009). Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 69(2). 413–416. 116 indexed citations

20.

Lawendy, Nervin, Sriram Krishnaswami, Rong Wang, et al.. (2009). Effect of CP‐690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers. The Journal of Clinical Pharmacology. 49(4). 423–429. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact